Comorbidity of fibromyalgia with medical and psychiatric disorders

doi:10.1016/0002-9343(92)90265-D

The American Journal of Medicine

Volume 92, Issue 4, April 1992, Pages 363-367

https://doi.org/10.1016/0002-9343(92)90265-D Get rights and content

Abstract

purpose: Patients with fibromyalgia have been reported to display high rates of several concomitant medical and psychiatric disorders, including migraine, irritable bowel syndrome, chronic fatigue syndrome, major depression, and panic disorder. To test further these and other possible associations, we assessed the personal and family histories of a broad range of medical and psychiatric disorders in patients with fibromyalgia.

patients and methods: Subjects were 33 women (mean age 42.1 years) who each met American College of Rheumatology criteria for fibromyalgia and presented to a rheumatologist at a tertiary referral center. They received the Structured Clinical Interview for DSM-III-R (SCID); a supplemental interview, in SCID format, for other medical and psychiatric disorders, including migraine, irritable bowel syndrome, and chronic fatigue syndrome; and an interview for family history of medical and psychiatric disorders.

results: Patients with fibromyalgia displayed high lifetime rates of migraine, irritable bowel syndrome, chronic fatigue syndrome, major depression, and panic disorder. They also exhibited high rates of familial major mood disorder.

conclusions: The finding that migraine, irritable bowel syndrome, chronic fatigue syndrome, major depression, and panic disorder are frequently comorbid with fibromyalgia is consistent with the hypothesis that these various disorders may share a common physiologic abnormality.

References (27)

DL Goldenberg
Psychologic studies in fibrositis
Am J Med
(1986)
WD Thompson et al.
An evaluation of the family history method for ascertaining psychiatric disorders
Arch Gen Psychiatry
(1982)
M Yunus et al.
Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls
Semin Arthritis Rheum
(1981)
SM Campbell et al.
Clinical characteristics of fibrositis. I. A “blinded,” controlled study of symptoms and tender points
Arthritis Rheum
(1983)
MB Yunus et al.
Association of primary fibromyalgia syndrome (PFS) with stress-related syndromes
Clin Res
(1985)
DL Goldenberg et al.
High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice
Arthritis Rheum
(1990)
F Wolfe et al.
The American College of Rheumatology 1990 criteria for the classification of fibromyalgia
Arthritis Rheum
(1990)
G Triadfilopoulos et al.
Bowel dysfunction in fibromyalgia syndrome
Dig Dis Sci
(1991)
JI Hudson et al.
Fibromyalgia and major affective disorder: a controlled phenomenology and family history study
Am J Psychiatry
(1985)
PN Tariot et al.
Psychiatric disorders in fibromyalgia
Am J Psychiatry
(1986)

S Alfici et al.

Primary fibromyalgia syndrome—a variant of depressive disorder?

Psychother Psychosom

(1989)

JI Hudson et al.

Affective spectrum disorder: does antidepressant response identify a family of disorders with a common pathophysiology?

Am J Psychiatry

(1990)

JI Hudson et al.

Fibromyalgia and psychopathology: is fibromyalgia a form of “affective spectrum disorder?”

J Rheumatol

(1989)

Cited by (477)

Clinical overlap between fibromyalgia and myalgic encephalomyelitis. A systematic review and meta-analysis
2022, Autoimmunity Reviews
Myalgic encephalomyelitis is an illness characterized by profound malaise after mental or physical effort occurring in patients already suffering from constant fatigue. On the other hand, widespread pain and widespread allodynia are the core fibromyalgia clinical features. There is controversy on these two syndromes alikeness.
Through the years, different diagnostic and/or classification criteria have been put forward to appraise both fibromyalgia and myalgic encephalomyelitis. The epidemiology of these two illnesses, and their overlap, may vary accordingly to the used definition. The most recent Wolfe et al. 2016 fibromyalgia diagnostic criteria incorporates three myalgic encephalomyelitis features including fatigue, waking unrefreshed and dyscognition.
The objective of this meta-analysis was to define the clinical overlap between fibromyalgia and myalgic encephalomyelitis based on a systematic literature review.
PubMed, Embase, Lilacs, and Cochrane data bases were searched on January 25, 2021 linking the medical subject heading “Fibromyalgia” to the following terms “chronic fatigue syndrome”, “myalgic encephalomyelitis” and “systemic exertion intolerance disease”. Our review included all original articles in which the clinical overlap between fibromyalgia and myalgic encephalomyelitis could be quantified based on recognized diagnostic or classification criteria. Articles scrutiny and selection followed the PRISMA guidelines. Each study quality was assessed according to GRADE recommendations. The global clinical overlap was calculated using a fixed effect model with inverse variance-weighted average method.
Twenty one publications were included in the meta-analysis. Reviewed studies were highly dissimilar in their design, objectives, sample size, diagnostic criteria, and/or outcomes yielding a 98% heterogeneity index. Nevertheless, the clinical overlap between fibromyalgia and myalgic encephalomyelitis was a well defined outcome that could be reliably calculated despite the high heterogeneity value. All reviewed publications had moderate GRADE evidence level. Most evaluated articles used the old 1990 Wolfe et al. fibromyalgia diagnostic criteria. Myalgic encephalomyelitis and fibromyalgia diagnoses overlapped in 47.3% (95% CI: 45.97–48.63) of the reported cases.
This meta-analysis found prominent clinical overlap between fibromyalgia and myalgic encephalomyelitis. It seems likely that this concordance would be even higher when using the most recent Wolfe et al. 2016 fibromyalgia diagnostic criteria.
The prevalence of psychiatric and chronic pain comorbidities in fibromyalgia: An acttion systematic review
2021, Seminars in Arthritis and Rheumatism
Fibromyalgia (FM) is a chronic widespread pain condition that overlaps with multiple comorbid health conditions and contributes to considerable patient distress. The aim of this review was to provide a systematic overview of psychiatric and chronic pain comorbidities among patients diagnosed with FM and to inform the development of recommendations for the design of clinical trials. Thirty-one, cross-sectional, clinical epidemiology studies that evaluated patients diagnosed with FM were included for review. None of the reviewed studies reported on the incidence of these comorbidities. Sample size-weighted prevalence estimates were calculated when prevalence data were reported in 2 or more studies for the same comorbid condition. The most prevalent comorbidity across all studies reviewed was depression/major depressive disorder (MDD) with over half of the patients included having this diagnosis in their lifetime (weighted prevalence up to 63%). In addition, nearly one-third of FM patients examined had current or lifetime bipolar disorder, panic disorder, or post-traumatic stress disorder. Less common psychiatric disorders reported included generalized anxiety disorder, obsessive compulsive disorder, and specific phobias (agoraphobia, social phobia). There were fewer studies that examined chronic pain comorbidities among FM patients, but when evaluated, prevalence was also high ranging from 39% to 76% (i.e., chronic tension-type or migraine headache, irritable bowel syndrome, myofascial pain syndrome, and temporomandibular disorders). The results of the review suggest that depression and chronic pain conditions involving head/jaw pain and IBS were elevated among FM patients compared to other conditions in the clinic-based studies. In contrast, anxiety-related disorders were much less common. Addressing the presence of these comorbid health conditions in clinical trials of treatments for FM would increase the generalizability and real-world applicability of FM research.
Approach as a key for success: Reduced avoidance behaviour mediates the effect of exposure therapy for fibromyalgia
2019, Behaviour Research and Therapy
Fibromyalgia (FM) is a prevalent chronic pain disorder associated with large suffering and substantial societal costs. Pain-related avoidance behaviour and hypervigilance to bodily symptoms are common in FM and contribute in maintaining and exacerbating the disorder. Exposure therapy targeting avoidance behaviours and hypervigilance has shown promise in the treatment of FM. The present study investigated mediators of treatment outcome in exposure therapy for FM. We used data from a randomised trial, where 140 participants were allocated to 10-week internet-delivered exposure therapy or to a waiting-list control condition. The main outcome variable (FM symptoms) and the hypothesized mediators (FM-related avoidance behaviour, mindful non-reactivity and FM-related worry) were measured weekly throughout treatment. Mediation analyses were conducted using linear mixed effects models with bootstrap replication and time-lagged analysis. Results indicated that all three process variables were significant mediators of FM severity. However, in the time-lagged analyses, only FM-related avoidance behaviour displayed a unidirectional relationship over time with FM symptoms, suggesting a causal effect. Thus, results illustrate that changes in avoidance behaviour mediate the outcome of exposure on FM symptoms, which implies that avoidance behaviour is an important treatment target in exposure therapy.
AAPT Diagnostic Criteria for Fibromyalgia
2019, Journal of Pain
Fibromyalgia (FM) is a common chronic pain disorder that presents diagnostic challenges for clinicians. Several classification, diagnostic and screening criteria have been developed over the years, but there continues to be a need to develop criteria that reflect the current understanding of FM and are practical for use by clinicians and researchers. The Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks (ACTTION) public-private partnership with the U.S. Food and Drug Administration (FDA) and the American Pain Society (APS) initiated the ACTTION-APS Pain Taxonomy (AAPT) to develop a diagnostic system that would be clinically useful and consistent across chronic pain disorders. The AAPT established an international FM working group consisting of clinicians and researchers with expertise in FM to generate core diagnostic criteria for FM and apply the multidimensional diagnostic framework adopted by AAPT to FM. The process for developing the AAPT criteria and dimensions included literature reviews and synthesis, consensus discussions, and analyses of data from large population-based studies conducted in the United Kingdom. The FM working group established a revised diagnosis of FM and identified risk factors, course, prognosis, and pathophysiology of FM. Future studies will assess the criteria for feasibility, reliability, and validity. Revisions of the dimensions will also be required as research advances our understanding of FM.
The ACTTION-APS FM taxonomy provides an evidence-based diagnostic system for FM. The taxonomy includes diagnostic criteria, common features, comorbidities, consequences, and putative mechanisms. This approach might improve the recognition of FM in clinical practice.
Prevalence of depressive disorder among patients with fibromyalgia: Systematic review and meta-analysis
2019, Journal of Affective Disorders
Citation Excerpt :
Although the applied assessment instrument may be among the most important reasons for the inconsistency, several other differences in methodological approaches may have influenced the results. All but one study was cross-sectional and most of the studies sampled their patients admitted to a rheumatology clinic or via referral to one (Gelonch et al., 2017; Hadlandsmyth et al., 2017; Arnold et al., 2006; Güven et al., 2005; Thieme et al., 2004; Burckhardt et al., 1994; Hudson et al., 1992; Hudson et al., 1985). However, three studies did not recruit their patients from outpatient secondary care, but instead via public media (e.g. ad in newspaper, email, phone calls) (Aparicio et al., 2013; Gormsen et al., 2010; Epstein et al., 1999).
It is acknowledged that fibromyalgia (FM) as a medical (rheumatological) disorder and major depressive disorder (MDD) as a mental disorder often co-occurs, but the inconsistency is prevailing at study-level and no overall estimate of the co-occurrence exist.
This systematic review and meta-analysis aimed to estimate the overall point- and life-time prevalence of MDD among FM patients based on structured clinical interviews (SCI); and to estimate the point-prevalence of MDD among FM patients based on screening symptom scales (SSS).
The electronical databases MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and PsycINFO were searched for papers that reported on prevalence of MDD among FM patients. Eligible studies were included in a random effects meta-analysis pooling the prevalence of depression.
The literature search identified 11 eligible studies for the meta-analysis. For SCI, the overall pooled point-prevalence (PP) was 25% (95% CI 19 to 31%), and life-time prevalence (LP) was 65% (95% CI 59 to 71%). When estimating the PP with self-administered SSS the overall pooled PP was 45% (95% CI 32 to 59%), and a single clinician–administered SSS yielded a PP of 23% (95% CI 10 to 41%). There was low inconsistency for the SCI and high inconsistency for the SSS.
One fourth of all FM patients had MDD, and more than half experienced MDD during their life-time according to clinician-administered instruments. Prevalence of MDD was almost twice as high when using self-administered symptom scales and may be likely to overestimate the co-occurrence.
Cost-Effectiveness and Cost-Utility of Internet-Delivered Exposure Therapy for Fibromyalgia: Results From a Randomized, Controlled Trial
2019, Journal of Pain
Fibromyalgia (FM) is a prevalent and debilitating chronic pain disorder associated with a substantial economic burden. Although there are several studies investigating the effectiveness of psychological treatments such as cognitive-behavioral therapy for FM, studies on cost-effectiveness are scarce. The aim of the present study was to investigate the cost-effectiveness of Internet-delivered exposure therapy (iExp) for FM. We used health economic data from a recently conducted randomized, controlled trial, where 140 participants were randomized to either iExp or a waitlist control (WLC) condition. Economic data were collected at pre-treatment, post-treatment, and at the 1-year follow-up. Treatment effectiveness in relation to costs were analyzed using both a societal perspective (including all direct and indirect costs) and a health care unit perspective (including only the direct treatment costs). Bootstrapped net benefit regression analyses were also conducted, comparing the difference in costs and effects between iExp and WLC, within different willingness-to-pay scenarios. Results showed that the incremental cost-effectiveness ratio was –$15,295, indicating that iExp was highly cost-effective as each successfully treated case (treatment responder) was associated with a substantial net reduction in costs. The robustness of the results was tested in 2 different sensitivity analyses, where iExp remained cost-effective, even in a willingness-to-pay-scenario of $0. We conclude that iExp is a cost-effective treatment that generates large societal cost savings.
Health-economic evaluations of psychological interventions for FM are scarce. This study is a cost-effectiveness analysis of Internet-delivered exposure therapy for patients with FM. Results showed that iExp was highly cost-effective compared with no treatment, where each successfully treated case generated a substantial societal cost saving.

View all citing articles on Scopus

^☆: This work was supported in part by National Institute of Mental Health Clinical Research Center Grant MH-36224.

^☆☆: This work was presented in part at the 54th Annual Scientific Meeting of the American College of Rheumatology, Seattle, Washington, October 1990.

View full text

Comorbidity of fibromyalgia with medical and psychiatric disorders☆,☆☆

Abstract

Am J Med

Arch Gen Psychiatry

Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls

Semin Arthritis Rheum

Clinical characteristics of fibrositis. I. A “blinded,” controlled study of symptoms and tender points

Arthritis Rheum

Association of primary fibromyalgia syndrome (PFS) with stress-related syndromes

Clin Res

High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice

Arthritis Rheum

The American College of Rheumatology 1990 criteria for the classification of fibromyalgia

Arthritis Rheum

Bowel dysfunction in fibromyalgia syndrome

Dig Dis Sci

Fibromyalgia and major affective disorder: a controlled phenomenology and family history study

Am J Psychiatry

Psychiatric disorders in fibromyalgia

Am J Psychiatry

Primary fibromyalgia syndrome—a variant of depressive disorder?

Psychother Psychosom

Affective spectrum disorder: does antidepressant response identify a family of disorders with a common pathophysiology?

Am J Psychiatry

Fibromyalgia and psychopathology: is fibromyalgia a form of “affective spectrum disorder?”

J Rheumatol